JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 243 filers reported holding JUNO THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.72 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $3,213,000 | -15.1% | 70,286 | -17.5% | 0.00% | 0.0% |
| Q3 2017 | $3,785,000 | +11.9% | 85,174 | -24.7% | 0.00% | 0.0% |
| Q2 2017 | $3,382,000 | +142.8% | 113,124 | +80.3% | 0.00% | – |
| Q1 2017 | $1,393,000 | +2631.4% | 62,746 | +2185.8% | 0.00% | – |
| Q4 2016 | $51,000 | -67.3% | 2,745 | -47.1% | 0.00% | – |
| Q3 2016 | $156,000 | -15.2% | 5,192 | +8.8% | 0.00% | – |
| Q2 2016 | $184,000 | -11.1% | 4,774 | -12.3% | 0.00% | – |
| Q1 2016 | $207,000 | -91.0% | 5,444 | -89.6% | 0.00% | -100.0% |
| Q4 2015 | $2,310,000 | -63.0% | 52,530 | -65.8% | 0.00% | -50.0% |
| Q3 2015 | $6,242,000 | -74.3% | 153,395 | -66.3% | 0.00% | -66.7% |
| Q2 2015 | $24,267,000 | +579.4% | 455,046 | +672.8% | 0.01% | +500.0% |
| Q1 2015 | $3,572,000 | +55.6% | 58,883 | +33.9% | 0.00% | 0.0% |
| Q4 2014 | $2,296,000 | – | 43,962 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |